Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
8000-42-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Botanical essential oil (Carum carvi)traditional carminative and gastrointestinal herbal preparation
Mechanism of action
Caraway essential oil contains volatile constituents including carvone and limonene. It is traditionally used for carminative and antispasmodic effects in the gastrointestinal tract; the precise pharmacological contribution of individual constituents is not fully established.
Indications / reported uses
Traditional symptomatic relief of mild gastrointestinal complaints such as bloating and flatulence in authorised herbal medicinal products; use is formulation- and jurisdiction-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Caraway Oil Environmental Risk Assessment (ERA) (the Caraway Oil ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.